Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 2/20 | 0.37 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.36 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619410 | 0.85 | FPR3 (0.43) | — | |
| SCHEMBL251473 | 0.84 | FFAR4 (0.43) | MAPTLMNAKMT2ATP53 | |
| SCHEMBL249626 | 0.79 | KMT2A (0.47) | MAPTLMNAKMT2AKCNQ2TP53 | |
| SCHEMBL27973304 | 0.71 | CYP1A2 (0.46) | KMT2ATP53 | |
| SCHEMBL10278543 | 0.70 | NSD2 (0.42) | MAPTLMNAKMT2ARET | |
| SCHEMBL1936344 | 0.69 | TRPV1 (0.54) | MAPTLMNAKMT2AKCNQ2TRPV1 | |
| SCHEMBL25189609 | 0.69 | KMT2A (0.51) | MAPTPOLBKMT2A | |
| SCHEMBL25193404 | 0.68 | ACP1 (0.36) | MAPTLMNAKMT2ATRPV1 | |
| SCHEMBL52399 | 0.68 | MMP13 (0.44) | — | |
| SCHEMBL2455269 | 0.67 | ACHE (0.66) | MAPTLMNAKMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401275-B1 | NAPHTHYRIDINE DERIVATIVES HAVING BRONCHODILATING ACTIVITY | RESPIRATORIUS AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| US-8415333-B2 | Bronchodilating diazaheteroaryls | RESPIRATORIOUS AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | RESPIRATORIUS AB (SE) | 2012-02-16 | — | — | US | disclosed |
| EP-2401275-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | Respiratorius AB (SE) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010097410-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | RESPIRATORIUS AB (SE) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | CHRM3, ADRB1, ADRB3 | MAPT 4262/4885POLB 3509/4885LMNA 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.